Current PSA level-Between 10 to 20 Posts on Medivizor
Navigation Menu

Current PSA level-Between 10 to 20 Posts on Medivizor

Comparing the outcomes of transvesical or posterior robot-assisted radical prostatectomy for localized prostate cancer.

Comparing the outcomes of transvesical or posterior robot-assisted radical prostatectomy for localized prostate cancer.

Posted by on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared 2 approaches of robot-assisted radical prostatectomy (RARP) for the treatment of localized prostate cancer (PCa). The authors concluded that both transvesical (T) and posterior (P) approaches had similar results in these patients. Some background Localized prostate cancer (PCa) is cancer that is...

Read More

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Posted by on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the role of 18F-fluciclovine-PET-CT versus conventional imaging (bone scan and either CT or MRI) alone for salvage radiotherapy (RT) after prostate surgery for the treatment of patients with localized prostate cancer (PCa). The data showed that including 18F-fluciclovine-PET-CT into the decision-making process for RT...

Read More

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients.  Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...

Read More

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Posted by on May 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...

Read More

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Posted by on Apr 18, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed and evaluated which hormonal therapy should be given first, abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) or enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that AAP followed by ENZ is more effective in delaying...

Read More

Comparing the activity and safety of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer

Comparing the activity and safety of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer

Posted by on Apr 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of lutetium-177 [177Lu]-PSMA-617 (177LuPSMA) versus cabazitaxel (Jevtana) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 177LuPSMA treatment showed a higher response with fewer side effects in these patients. Some...

Read More

Searching for patients with confined prostate cancer to trial a cryoablation procedure

Searching for patients with confined prostate cancer to trial a cryoablation procedure

Posted by on Mar 13, 2021 in Prostate cancer | 0 comments

In a nutshell This trial is looking to examine the use of a new treatment software (UroNAV Ablation) system in treating confined prostate cancer with cryoablation. The main outcomes to be measured will be device/treatment-related complications and tumor control. This trial is being carried out in New York, US.  The details Localized...

Read More

Do statins help the treatment of patients with prostate cancer using androgen-deprivation therapy?

Do statins help the treatment of patients with prostate cancer using androgen-deprivation therapy?

Posted by on Jan 24, 2021 in Prostate cancer | 0 comments

In a nutshell This study explored the outcomes of statin (cholesterol-lowering drugs) treatment in patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The authors found that the combination of statins and ADT improved the outcomes of these patients and intermittent ADT (IADT) increased the time...

Read More

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Posted by on Dec 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is evaluating the effectiveness and safety of combining nivolumab (Opdivo) with docetaxel (Taxotere) and prednisone (Deltasone) in men with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes to be evaluated will be survival without cancer worsening and overall survival. The details CRPC is a difficult...

Read More

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Posted by on Aug 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...

Read More

Searching for patients with prostate cancer to test low-dose or high-dose brachytherapy

Posted by on May 28, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 3 trial is examining the effectiveness and safety of low dose rate (LDR) vs high dose rate (HDR) prostate brachytherapy (BT) for patients with prostate cancer (PC). The main outcome to be measured will be the quality of life in terms of urinary symptoms. This trial is recruiting in British Columbia,...

Read More